- Delic Holdings subsidiary, Ketamine Wellness Centers, announced plans to open two new clinics in the coming weeks
- The clinics, to be located in Salt Lake City, Utah and Reno, Nevada will take KWC’s total clinic count to 14, forming part of the company’s plan to open 13 new ketamine infusion clinics across the country over the next 18 months
- Following Delic’s keynote ‘Meet Delic’ conference on Nov. 6-7, CEO Matt Stang announced plans to attend the upcoming HC Wainwright Bioconnect Virtual Conference as well as CEM’s 8th annual AlphaNorth Capital Conference in January 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has revealed that its wholly owned ketamine infusion clinic chain, Ketamine Wellness Centers LLC (“KWC”), will open two new clinics in Salt Lake City, Utah and Reno, Nevada, by February 2022. Ketamine Wellness Centers LLC, which was acquired by Delic Holdings in September 2021, currently boasts 10 ketamine infusion treatment clinics located across eight U.S. states, having cumulatively delivered over 60,000 treatments to date across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington.
KWC’s Salt Lake City clinic, which is set to be located in the suburb of Taylorsville at 6087 South Redwood Road, is expected to open on Jan. 10, 2022. With a capacity of up to seven treatment rooms, the facility will be one of KWC’s largest clinics in the U.S. Meanwhile, KWC Reno, which is scheduled to open in February 2022, will be the company’s second clinic in Nevada and has been strategically located to serve both local Nevada residents as well as patients domiciled in the larger California markets who currently do not have access to affordable in-state providers.
“Offering accessible, personalized and high-quality care is integral to Ketamine Wellness Centers’ mission, and we look forward to supporting the emotional wellness of new patients in Utah and Nevada,” said Kevin Nicholson, CEO of KWC and Chief Operating Officer for Delic.
Delic will open 13 ketamine infusion clinics across the country over the next 18 months, adding to the company’s existing portfolio which comprises of 12 KWC clinics as well as two clinics operated by subsidiary, Ketamine Infusion Centers LLC (“KIC”), with the latter centers located in California and Arizona, respectively. As such, the company plans to further expand access to millions who can now benefit from new medicines and treatments for a broad array of mental health conditions, building on the company’s reputation as a central hub of education, media and cultural conversations around these novel treatments.
Delic Holdings also seized on the opportunity to announce further details regarding Matt Stang, Delic’s co-founder and CEO’s participating at the upcoming HC Wainwright Bioconnect Virtual Conference as well as CEM’s 8th annual AlphaNorth Capital conference in January.
Stang will present at the HC Wainwright Bioconnect Virtual Conference, which will take place digitally between Jan. 10-13, 2022. At the conference, Stang is set to elaborate on Delic’s expansion strategy and industry outlook heading into the new year in addition to hosting one-on-one meetings with investors. To access Delic’s presentation at the virtual HC Wainwright Bioconnect Conference, investors can register at the following link: https://hcwevents.com/bioconnect/
Matt Stang is also set to attend CEM’s 8th Annual AlphaNorth Capital Conference, which is set to be held in Nassau, Bahamas on Jan. 21-23, 2022. The conference has garnered a well-established reputation for connecting growth-stage companies — including those within technology and biotech — with high-level investors. Stang will host one-on-one meetings that will enable investors to gain closer insights into Delic’s growth opportunities in the coming year. Investors and issuers interested in registering for the attendee waitlist can visit https://cem.ca/conference/alphanorth-capital-event/.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.